Publication in JMIR Mental Health
MODIA™ has been published in the well-renowned journal JMIR Mental Health. The paper outlines the development and features of MODIA™.
|
Short facts |
|
|
Technology |
GAIA´s proprietary artificial intelligence (AI)-expert system, broca® |
|
Indication |
Opioid use disorder (OUD) |
|
Period of use |
6 months |
|
Commercial rights |
Worldwide. US launch initiated Q4 2021. |
|
Partner |
Developed together with |
|
Key advantages |
|
|
Pivotal study |
Large pivotal study initiated in June 2021 where the efficacy of MODIA™ is evaluated along with bup/nal pharma treatment |
Unmet need
The medically assisted treatment of opioid use disorder requires a complete treatment plan, including effective pharmaceutical treatment, such as Orexo’s commercially available ZUBSOLV®, along with counseling or psychosocial support. The access and quality of counseling and psychosocial support remain one of the main barriers to successful treatment in many areas of the US. Orexo believes that the fully-automated digital therapy can become a valuable addition to existing treatment plans, which will improve patients’ access to treatment and overall treatment outcomes.
MODIA™ is being tested in a pivotal study
Large pivotal study initiated in June 2021, where the efficacy of MODIA™ is evaluated along with bup/nal pharma treatment.
MODIA's product website
Learn more about MODIA™ at the digital therapeutic's product website. There you can find additional information about the product and sign up for updates about the therapeutic.
Related links
About GAIA
The press release communicating the partnership
https://orexo.com/en/media/press-releases?releaseId=B4A65108A4D7F345
Press release regarding the first patient in MODIA's pivotal study
https://mb.cision.com/Main/694/3377614/1439218.pdf